Terug naar events

IMI stakeholder forum 2016

IMI stakeholder forum 2016
28 -29 September 2016
Hotel Crown Plaza - Le Palace in Brussels, Belgium

Every year, the IMI Stakeholder Forum gathers IMI’s stakeholders in health and medicines R&D and provides them with an opportunity to learn about and discuss IMI’s latest activities and plans.

The IMI Stakeholder Forum will open its doors on Wednesday 28 September at 13:00, and draw to a close on Thursday 29 September at 17:00.

Wednesday 28 September

Download the agenda of day 1  of the IMI Stakeholder Forum.

Raju Kucherlapati, Paul C. Cabot Professor of Genetics and Professor of Medicine at the Harvard Medical School, will provide the keynote lecture.

IMI Scientific Officers will present the topics of IMI’s upcoming 10th Call for proposals, followed by a networking cocktail and dinner where participants will have the opportunity to meet IMI staff and network with potential partners around the topics of Call 10.

The IMI legal team will provide a presentation on the IMI Intellectual Property rules. 

A panel including IMI project participants, SMEs and IMI Associated Partners will debate the advantages for participating in an IMI project and discuss advice for applicants with Hugh Laverty, IMI’s Head of Scientific Operarions.


Thursday 29 September

The second day will be dedicate to parallel consultative workshops on strategic research areas, bringing together IMI stakeholders to shape the future of IMI’s programme. The four parallel consultations will cover advanced therapies, biopreparedness (more info below), digital health and oncology (more info below).


WORKSHOP: Biopreparedness

Recent epidemics of existing and new diseases have emerged in different regions of the world, including not only the Ebola and Zika viruses, but also the Dengue fever in Southern Europe and the Yellow fever outbreak in Angola. The patterns of these phenomena are linked to a complex variety of factors, including climate change trends, vaccine supplies and uptake, and geopolitical challenges. A number of organisations have a role to play in tackling such public health emergencies. IMI is among these. But while programmes like IMI cannot fully respond to all of these issues, a public-private partnership could offer the advantages, flexibility and complementary assets to make a difference. The goal of this consultative workshop is to gather input from stakeholders involved in public health emergencies in order to ascertain whether a public-private supported platform could play a role, and if so – how, in selecting rapid approaches to treatment and intervention options. This consultation workshop is jointly organised by IMI, the European Commission and EFPIA. Confirmed speakers:

Herman Goossens, Professor of Microbiology, University of Antwerp;
Line Matthiessen, Head of Unit, Fighting infectious diseases and advancing public health, DG Research & Innovation, European Commission;
Marie-Paule Kieny, Assistant Director-General – Health Systems and Innovation, World Health Organization (WHO);
John-Arne Røttingen, CEPI – Coalition for Epidemic Preparedness Innovations, c/o Norwegian Institute of Public Health;
Piotr Kramarz, Deputy Chief Scientist, European Centre for Disease Prevention and Control (ECDC)
Jean Lang, Associate Vice President, Sanofi Pasteur;
Michael Makanga, Executive Director, European & Developing Countries Clinical Trials Partnership (EDCTP);
Mark Miller, Chief Medical Officer, BioMerieux;
Philippe Denoel, Director, External R&D at GlaxoSmithKline Biologicals.

WORKSHOP: Oncology

This workshop is organised with the IMI Strategic Governing Group (SGG) Oncology, in order to better understand the current gaps in oncology research; to assess whether an IMI project would be considered the appropriate tool to address any of these gaps; to discuss, if an IMI Call was to focus on this topic, what would be the most appropriate and effective Call process and project strategies. Confirmed speakers:

Stefan J. Scherer, Vice-President Global Head Correlative Science, Novartis; Chair of the IMI Strategic Governing Group (SGG) Oncology;
Denis Lacombe, Director General, European Organisation for Research and Treatment of Cancer (EORTC);
Françoise Meunier, Director Special Projects, European Organisation for Research and Treatment of Cancer (EORTC);
Alexander Eggermont, General Director, Gustave Roussy:
David Cameron, Chair of Oncology/Head of Cancer Services, School of Molecular, Genetic and Population Health Sciences, University of Edinburgh;
Jan Geissler, Director of EUPATI, the European Patients Academy on Therapeutic Innovation;
Raju Kucherlapati, Paul C. Cabot Professor of Genetics, Professor of Medicine, Harvard Medical School

More info: click here